2023 End-of-Year Review: CNS & Rare Disease Insights
)
)
‘Although it has definitely been a tricky and challenging year for neuroscience – and biopharma in general – there have been some amazing successes that are still worth celebrating.’
Working within the CNS & Rare Disease space for our Life Sciences team, Paula Doust Alba has had a busy year. In this video, she gives us her end-of-year review for 2023 – and while it hasn’t always been plain sailing, breakthroughs in Alzheimer’s have been particularly gratifying to note.
Check out this clip to hear Paula reflect on the demand for clinical talent and experienced CMOs, fundraising and development breakthroughs – in addition to her predictions for 2024!
Tags:
- Insight
- Market Update
- Executive Search
)
Cristian Owen joined Venari Partners in 2019. An expert in recruitment for digital health, he has been a trusted partner to many emerging and high-growth healthtech companies across the US and Europe. This spans SaaS, digital therapeutics, AI, virtual care, data (RWE), and healthcare IT, which he uses to help companies build high-performing leadership teams in strategy, BD, operations, and commercial roles. Cristian is well placed to advise on US GTM expansion for European healthtech companies, C-suite, VP-, and director-level recruitment, board appointments, and succession planning. He also provides specialised solutions including interim solutions, market mapping, compensation benchmarking, and leadership and organisational assessments. Outside of Venari Partners, as a former chef, he has a tremendous passion for food and loves to experiment with cooking and eating as many different cuisines as possible.
View Full Profile)
)
)
)
)
)
